**Dr Samantha Campbell** - **Assessing the safety and efficacy of advanced therapies to treat inflammatory bowel disease in patients with a liver transplant.**

The EASL conference was a highly enriching experience that provided both practical knowledge and strategic insights for enhancing my daily clinical work. The opportunity to network with experts, learn about innovative treatments, and reflect on best practices was invaluable. In addition, it was a fantastic opportunity to catch up with colleagues, past and present. This all took place in a beautiful city, Amsterdam. I am already looking forward to EASL 2026 in Barcelona.

The conference presented the most recent advancements in hepatology, including liver diseases such cholestatic and autoimmune conditions (PSC, PBC, AIH), MASLD and liver cancer. The in-depth sessions on new treatment modalities and emerging diagnostic techniques were particularly beneficial. In particular, the winner of the best oral clinical presentation, introducing a novel 3-in-1 metabolomic test for PSC and CCA early diagnosis and risk stratification is groundbreaking. The results of the MITIGATE trial were presented – an international, randomised, blinded, placebo-controlled phase 3 trial that evaluated the safety and efficacy of inebilizumab treatment in adults with IgG4-RD. The results were promising, and showed a reduced risk of disease flares and reduced annualised flare rates.

The clinical hands-on endoscopy session was excellent, providing me with the opportunity to practice on pig models, supervised by experts from around the world – skills I can directly apply to my clinical practice. I particularly enjoyed sessions that focused on innovative therapies such as immunotherapy, and advanced drug development (particularly in the field of MASLD, including latest updates on FGF21 agonist and small-molecule drug and fatty acid synthase inhibitors). Seeing how these technologies are being integrated into clinical practice was inspiring and reinforced the need to stay informed about emerging treatment strategies.

I ensured I attended presentations delivered by colleagues to show support and to learn from them - it was lovely to see them flourish. The solidarity presented from the international audience of the conference was amazing. I loved the experience of poster tours, and having the opportunity to showcase my work as a poster presentation. During the recognition awards, there were standing ovations and the atmosphere was incredible. I felt honoured to be a part of it.

Another highlight of the conference was meeting and interacting with leading experts in hepatology. The delicious coffee was a close second! These conversations allowed me to not only expand my professional network but also engage in insightful discussions about ongoing research and future directions in liver disease treatment. The evening events, with King’s College Hospital colleagues, and the CLDF reception was an excellent opportunity to catch up with colleagues, past and present, from all over the world – UK, to Belgium to Canada and more. See you in Barcelona!

A person standing next to a white board

AI-generated content may be incorrect.A group of people posing with large wooden letters

AI-generated content may be incorrect.